Title | Bronchodilator Responsiveness in Tobacco-Exposed People With or Without COPD. |
Publication Type | Publication |
Year | 2023 |
Authors | Fortis S, Quibrera PM, Comellas AP, Bhatt SP, Tashkin DP, Hoffman EA, Criner GJ, Han MK, R Barr G, Arjomandi M, Dransfield MB, Peters SP, Dolezal BA, Kim V, Putcha N, Rennard SI, Paine R, Kanner RE, Curtis JL, Bowler RP, Martinez FJ, Hansel NN, Krishnan JA, Woodruff PG, Barjaktarevic IZ, Couper D, Anderson WH, Cooper CB |
Corporate Authors | Subpopulations and Intermediate Outcome Measures in COPD Study Investigators |
Journal | Chest |
Volume | 163 |
Issue | 3 |
Pagination | 502-514 |
Date Published | 2023 Mar |
ISSN | 1931-3543 |
Keywords | asthma, Bronchodilator Agents, Forced Expiratory Volume, Humans, Pulmonary Disease, Chronic Obstructive, Retrospective Studies, Tobacco, Vital Capacity |
Abstract | BACKGROUND: Bronchodilator responsiveness (BDR) in obstructive lung disease varies over time and may be associated with distinct clinical features.RESEARCH QUESTION: Is consistent BDR over time (always present) differentially associated with obstructive lung disease features relative to inconsistent (sometimes present) or never (never present) BDR in tobacco-exposed people with or without COPD?STUDY DESIGN AND METHODS: We retrospectively analyzed data from 2,269 tobacco-exposed participants in the Subpopulations and Intermediate Outcome Measures in COPD Study with or without COPD. We used various BDR definitions: change of ≥ 200 mL and ≥ 12% in FEV (FEV-BDR), change in FVC (FVC-BDR), and change in in FEV, FVC or both (ATS-BDR). Using generalized linear models adjusted for demographics, smoking history, FEV % predicted after bronchodilator administration, and number of visits that the participant completed, we assessed the association of BDR group: (1) consistent BDR, (2) inconsistent BDR, and (3) never BDR with asthma, CT scan features, blood eosinophil levels, and FEV decline in participants without COPD (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage 0) and the entire cohort (participants with or without COPD).RESULTS: Both consistent and inconsistent ATS-BDR were associated with asthma history and greater small airways disease (%parametric response mapping functional small airways disease) relative to never ATS-BDR in participants with GOLD stage 0 disease and the entire cohort. We observed similar findings using FEV-BDR and FVC-BDR definitions. Eosinophils did not vary consistently among BDR groups. Consistent BDR was associated with FEV decline over time relative to never BDR in the entire cohort. In participants with GOLD stage 0 disease, both the inconsistent ATS-BDR group (OR, 3.20; 95% CI, 2.21-4.66; P < .001) and consistent ATS-BDR group (OR, 9.48; 95% CI, 3.77-29.12; P < .001) were associated with progression to COPD relative to the never ATS-BDR group.INTERPRETATION: Demonstration of BDR, even once, describes an obstructive lung disease phenotype with a history of asthma and greater small airways disease. Consistent demonstration of BDR indicated a high risk of lung function decline over time in the entire cohort and was associated with higher risk of progression to COPD in patients with GOLD stage 0 disease. |
DOI | 10.1016/j.chest.2022.11.009 |
Alternate Journal | Chest |
PubMed ID | 36395858 |
PubMed Central ID | PMC9993341 |
Grant List | HHSN268200900019C / HL / NHLBI NIH HHS / United States U24 HL141762 / HL / NHLBI NIH HHS / United States HHSN268200900016C / HL / NHLBI NIH HHS / United States P30 ES005605 / ES / NIEHS NIH HHS / United States HHSN268200900015C / HL / NHLBI NIH HHS / United States R21 EB027891 / EB / NIBIB NIH HHS / United States HHSN268200900014C / HL / NHLBI NIH HHS / United States TL1 TR001883 / TR / NCATS NIH HHS / United States HHSN268200900018C / HL / NHLBI NIH HHS / United States U01 HL137880 / HL / NHLBI NIH HHS / United States UG3 HL155806 / HL / NHLBI NIH HHS / United States R01 HL150023 / HL / NHLBI NIH HHS / United States K24 HL138188 / HL / NHLBI NIH HHS / United States HHSN268200900020C / HL / NHLBI NIH HHS / United States HHSN268200900017C / HL / NHLBI NIH HHS / United States R01 HL151421 / HL / NHLBI NIH HHS / United States R01 AI129958 / AI / NIAID NIH HHS / United States HHSN268200900013C / HL / NHLBI NIH HHS / United States |
Bronchodilator Responsiveness in Tobacco-Exposed People With or Without COPD.
MS#:
MS259
Manuscript Full Title:
Bronchodilator Responsiveness in Tobacco-Exposed People With or Without COPD.
ECI:
Manuscript Status:
Published and Public